Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?

Blood

Volumn 113, Issue 24, 2009, Pages 6263-6264

  Savani, Bipin N ^a   Pohlmann, Paula R ^a   Jagasia, Madan ^a   Chinratanalab, Wichai ^a   Kassim, Adetola ^a   Engelhardt, Brian ^a   Greer, John ^a   Schuening, Friedrich ^a   Goodman, Stacey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; RAPAMYCIN; RITUXIMAB; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; DONOR LYMPHOCYTE INFUSION; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LETTER; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PERIOPERATIVE PERIOD; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS REACTIVATION; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; NOTE; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 67650351903     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-04-213892     Document Type: Letter

References (12)

1. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113:4992-5001.
2. Kindwall-Keller TL, Cooper BW, Laughlin MJ, et al. Preemptive rituximab treatment may reduce the incidence of post-transplant lymphoproliferative disorders (PTLD) in patients with EBV reactivation after allogeneic stem cell transplantation [abstract]. Biol Blood Marrow Transplant. 2009;15:91.
3. Vianna RM, Mangus RS, Fridell JA, et al. Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation. Transplantation. 2008;85:1290-1293.
4. Nishio M, Fujimoto K, Yamamoto S, et al. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur J Haematol. 2006;77:226-232. (Pubitemid 44181385)
5. Khouri IF. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2006;390-397.
6. Arai S, Sahaf B, Jones C, et al. Rituximab infusion two months after total lymphoid irradiation-antithymocyte globulin (TLI-ATG) nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD [abstract]. Biol Blood Marrow Transplant. 2007;13:103.
7. Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide with or without low dose TBI for alternative donor transplants in acquired aplastic anemia (SAA): a report from the EBMT-SAAWorking Party [abstract]. Biol Blood Marrow Transplant. 2009;15:5.
8. Gribben JG. Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2008;15:53-58.
9. Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A. 2000;97:4285-4290. (Pubitemid 30226125)
10. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation. 1995;60:264-270.
11. Garcia VD, Bonamigo Filho JL, Neumann J, et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transplant Int. 2003;16:202-206. (Pubitemid 36682198)
12. Armand P, Gannamaneni S, Kim HT, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008;26:5767-5774.